MedTrace Logo

Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years Old

NCT05145166 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2021-12-06

No results posted yet for this study

Summary

This study of live attenuated mumps vaccines is an observational study in which active monitoring and passive monitoring were combined to conduct safety observation.The live attenuated mumps vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The purpose of this study is to evaluate the safety of live attenuated mumps vaccines after large-scale application and accumulate safety data for the application of live attenuated mumps vaccines,and provide scientific basis for the formulation of vaccine immunization prevention strategies.

Conditions

Interventions

BIOLOGICAL

Safety group

All of the participants(N=10000) received one dose of live attenuated mumps vaccine.Vaccine will given by single intramuscular injection(0.5 ml) on day 0.

Sponsors & Collaborators

  • Sinovac (Dalian) Vaccine Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Weijun Hu, Master · Shaanxi Provincial Center for Disease Control and Prevention

Eligibility

Max Age
14 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-06
Primary Completion
2020-11-06
Completion
2021-03-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05145166 on ClinicalTrials.gov